查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1375981

特發性血小板減少紫斑症治療藥物市場規模、佔有率、趨勢分析報告：依疾病類型、地區、細分市場預測，2023-2030年

Idiopathic Thrombocytopenic Purpura Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Corticosteroids, IVIG, Anti-D Immunoglobulins, TPO-RA, Others), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 60 Pages | 商品交期: 2-10個工作天內

價格

特發性血小板減少紫斑症治療藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球特發性血小板減少紫斑症藥物市場將達到9.149億美元，2023年至2030年年複合成長率為5.0%，預計。

隨著 IVIG 和 TPO-RA 類新藥的推出，研究和開發的增加預計將推動預測期內的成長。此外，旨在鼓勵新產品開發的美國孤兒藥法案等政府法規預計將推動成長。

業界對聯合治療聯合治療的需求正在增加，因為與其他治療方法相比，聯合療法顯示出更高的效率。此外，它具有成本效益，有助於限制與個別治療層級相關的副作用。主要聯合治療包括地塞米松和利妥昔單抗、地塞米松和TPO-RA、IVIG和皮質類固醇。脾切除術（切除脾臟的手術）旨在減少抗血小板抗體​​的數量，預計將推動需求。皮質類固醇通常用於治療特發性血小板減少紫斑症。皮質類固醇的使用率非常高，被認為是治療ITP患者的第一線藥物。

特發性血小板減少紫斑症治療市場報告亮點

  • 由於給藥艾曲波帕和羅米司亭治療的患者的高反應率，TPO-RA 預計將出現顯著成長，從 2023 年到 2030 年，年複合成長率將超過 6.6%。此外，隨著2015年Avatrombopag的商業化，對TPO-RA的需求預計將增加。此外，TPO-RA 治療脾切除患者復發的能力預計將推動未來年度的需求。
  • 北美市場佔據主導地位，2022 年銷售佔有率最大，為 39.9%。
  • 預計亞太地區在預測期內將以 6.2% 的最快年複合成長率成長。
  • 由於積極的政府配合措施以及澳洲和日本先進的醫療基礎設施，亞太地區預計在未來年度將顯著成長。此外，中國和印度等新興市場預計將推動成長，因為有許多開拓的機會。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 特發性血小板減少紫斑症治療藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 特發性血小板減少紫斑症治療藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 特發性血小板減少紫斑症治療藥物市場：疾病類型估計與趨勢分析

  • 特發性血小板減少紫斑症治療藥物市場，依疾病類型分類的要點
  • 特發性血小板減少紫斑症治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 急性ITP
  • 慢性的
  • 其他

第5章 特發性血小板減少紫斑症治療藥物市場：產品估算與趨勢分析

  • 特發性血小板減少紫斑症治療藥物市場，依產品分類的要點
  • 特發性血小板減少紫斑症治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 皮質類固醇
  • IVIG
  • 抗D免疫球蛋白
  • TPO-RA
  • 其他

第6章 特發性血小板減少紫斑症治療藥物市場：區域估計與趨勢分析

  • 區域展望
  • 按地區分類的特發性血小板減少紫斑症治療藥物市場：主要市場點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭分類
    • Amgen Inc.
    • F. Hoffmann-La Roche Ltd
    • Grifols, SA
    • GSK plc.
    • Shangxian Minimal Invassive Inc.
    • INTROMEDIC
    • Medtronic
    • FUJIFILM Holdings Corporation
    • Olympus Corporation
    • JINSHAN Science & Technology (Group) Co., Ltd.
Product Code: 978-1-68038-289-1

Idiopathic Thrombocytopenic Purpura Therapeutics Market Growth & Trends:

The global idiopathic thrombocytopenic purpura therapeutics market is expected to reach USD 914.9 million by 2030, expanding at a CAGR of 5.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rising R&D leading to the introduction of new drugs for IVIG and TPO-RA classes is expected to propel growth over the forecast period. In addition, government regulation such as the Orphan Drug Act in the United States with an aim to encourage new product development is projected to fuel growth.

The industry is characterized by a rising demand for combination therapies as they exhibit higher efficiency as compared to other treatments. Moreover, they are cost-efficient and help curb side effects associated with individual therapeutic classes. Some of the major combination therapies are dexamethasone and rituximab, dexamethasone and TPO-RA, IVIG, and corticosteroids. Splenectomy, the procedure to remove the spleen is aimed at reducing the amount of anti-platelet antibodies, is expected to fuel demand. Corticosteroids are regularly used in idiopathic thrombocytopenic purpura treatment. Since corticosteroid are considered to be the first line of therapy for patients suffering from ITP, the usage rates of corticosteroid are very high.

Idiopathic Thrombocytopenic Purpura Therapeutics Market Report Highlights:

  • TPO-RA is likely to witness substantial growth, growing at a CAGR of over 6.6% from 2023 to 2030 owing to high response rates exhibited by patients administered with Eltrombopag and Romiplostim. Moreover, demand for TPO-RA is expected to increase due to the commercialization of Avatrombopag in 2015. In addition, the ability of TPO-RA to cater to splenectomized patients witnessing relapses is expected fuel demand over the next six years.
  • North America dominated the market and accounted for the largest revenue share of 39.9% in 2022.
  • Asia Pacific is expected to grow at the fastest CAGR of 6.2% over the forecast period.
  • Asia Pacific is expected to experience substantial growth over the next six years, owing to the presence of favorable government initiatives, and sophisticated healthcare infrastructure in Australia and Japan. In addition, the presence of vast untapped opportunities in emerging markets such as China and India is expected to propel growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Disease Type
    • 1.1.2. Product
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease type outlook
    • 2.2.2. Product outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Idiopathic Thrombocytopenic Purpura Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Disease Type Estimates & Trend Analysis

  • 4.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Disease Type Key Takeaways
  • 4.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Acute ITP
    • 4.3.1. Acute ITP market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.4. Chronic
    • 4.4.1. Chronic market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.5. Others
    • 4.5.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 5. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Product Estimates & Trend Analysis

  • 5.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Product Key Takeaways
  • 5.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Corticosteroids
    • 5.3.1. Corticosteroids market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.4. IVIG
    • 5.4.1. IVIG market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.5. Anti-D Immunoglobulins
    • 5.5.1. Anti-D Immunoglobulins market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.6. TPO-RA
    • 5.6.1. TPO-RA market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 6. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. U.K.
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Amgen Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Disease Type benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. F. Hoffmann-La Roche Ltd
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Disease Type benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Grifols, S.A.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Disease Type benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. GSK plc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Disease Type benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Shangxian Minimal Invassive Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Disease Type benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. INTROMEDIC
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Disease Type benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Medtronic
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Disease Type benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. FUJIFILM Holdings Corporation
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Disease Type benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Olympus Corporation
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Disease Type benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. JINSHAN Science & Technology (Group) Co., Ltd.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Disease Type benchmarking
      • 7.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 3 North America idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America idiopathic thrombocytopenic purpura therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 5 U.S. idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 6 U.S. idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 7 Canada idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 8 Canada idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 9 Europe idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 10 Europe idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 11 Europe idiopathic thrombocytopenic purpura therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 12 Germany idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 13 Germany idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 14 UK idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 15 UK idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 16 France idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 17 France idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 18 Italy idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 19 Italy idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 20 Spain idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 21 Spain idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 22 Denmark idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 23 Denmark idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 24 Sweden idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 25 Sweden idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 26 Norway idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 27 Norway idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by country, (USD Million) 2018 - 2030
  • Table 31 Japan idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 32 Japan idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 33 China idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 34 China idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 35 India idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 36 India idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 37 Thailand idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 38 Thailand idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 39 South Korea idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 40 South Korea idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 41 Latin America idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 42 Latin America idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 43 Latin America idiopathic thrombocytopenic purpura therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 44 Brazil idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 45 Brazil idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 46 Mexico idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 47 Mexico idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 48 Argentina idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 49 Argentina idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 50 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 51 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by country, (USD Million) 2018 - 2030
  • Table 53 Saudi Arabia idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 55 South Africa idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 56 South Africa idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 57 UAE idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 58 UAE idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 59 Kuwait idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 60 Kuwait idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Idiopathic thrombocytopenic purpura therapeutics: market outlook
  • Fig. 9 Idiopathic thrombocytopenic purpura therapeutics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Idiopathic thrombocytopenic purpura therapeutics market driver impact
  • Fig. 15 Idiopathic thrombocytopenic purpura therapeutics market restraint impact
  • Fig. 16 Idiopathic thrombocytopenic purpura therapeutics market strategic initiatives analysis
  • Fig. 17 Idiopathic thrombocytopenic purpura therapeutics market: Disease type movement analysis
  • Fig. 18 Idiopathic thrombocytopenic purpura therapeutics market: Disease type outlook and key takeaways
  • Fig. 19 Acute ITP market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Chronic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Idiopathic thrombocytopenic purpura therapeutics market: Product type movement analysis
  • Fig. 23 Idiopathic thrombocytopenic purpura therapeutics market: Product type outlook and key takeaways
  • Fig. 24 OGIB market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 IVIG market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Anti-D immunoglobulins market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 TPO-RA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Global idiopathic thrombocytopenic purpura therapeutics market: Regional movement analysis
  • Fig. 30 Global idiopathic thrombocytopenic purpura therapeutics market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)